Nephrol Dial Transplant (1993) 8: 1326-1332
© 1993 European Renal Association-European Dialysis and Transplant Association
research-article
Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial
1Division of Nephrology and Dialysis, IRCCS, Ospedale Maggiore Milan 2Clinica Pediatrica G. e D. De Marchi Milan 3Ospedale Bambin Gesù Rome 4Istituto G. Gaslini Genoa 5I Policlinico Naples 6Ospedale Civile Padua 7Ospedale Niguarda Milan 8Ospedale S. Michele Cagliari 9Ospedale Borgo Trento Verona 10Policlinico Umberto I Rome 11Nuovo Policlinico Naples 12Ospedale Policlinico Bari 13Ospedale dei Bambini Umberto I Brescia 14Medical Department Sandoz P.F. Milan, Italy
Correspondence and offprint requests to: Correspondence and offprint requests to: Prof. C. Ponticelli, Divisione di Nefrologia e Dialisi—Pad. CROFF, IRCCS, Ospedale Maggiore, Via della Commenda, 15, 20122 Milano MI, Italy.
OBJECTIVE: To compare the efficacy (maintenance of remission), safety and tolerability of cyclosporin (CsA) with those of cyclophosphamide in patients with steroid-dependent or frequently relapsing nephrotic syndrome (NS).
DESIGN: Open, prospective, randomized, multicentre, controlled study for parallel groups, stratified for adults and children. The setting was in nephrological departments in Italy.
SUBJECTS AND INTERVENTIONS: Seventy-three patients with steroid-sensitive idiopathic NS admitted to the study were randomly assigned to cyclophosphamide (2.5 mg/kg/day) for 8 weeks or CsA (5 mg/kg/day in adults, 6 mg/kg/day in children) for 9 months, tapered off by 25% every month until complete discontinuation at month 12. Seven patients lost to follow up were not considered in the analysis. The remaining 66 patients were followed up for 3–24 months after randomization.
MAIN OUTCOME MEASURES: Relapse-free survival; number of N.S. relapses/patient/year; cumulative dose of prednisone/patient; laboratory investigations (kidney and liver functions, haematological parameters); incidence of adverse events.
RESULTS: At month 9, 26 of 35 CsA-treated patients were still in complete remission and a further five patients were in partial remission; 18 of 28 cyclophos-phamide-treated patients were in complete remission, and one in partial remission (P=NS). No difference between adults and children was seen with either treatment. The risk of relapse was similar between frequent relapsers (19 of 22) and steroid-dependent patients (8 of 14) given CsA, and those given cyclophosphamide (5 of 15 and 6 of 15). The mean number of relapses per year and the mean dose of prednisone per year were significantly less (P<0.001) in both groups for the experimental year than for the year before randomization. At 2 years, 25% of the patients given CsA (50% adults and 20% children) and 63% of those given cyclophosphamide (40% adults and 68% children) had not had any relapse of NS.
Tolerance to the two drugs was generally good. The CsA-related side-effects were mild and disappeared after drug discontinuation.
CONCLUSIONS: This study shows that both treatments are effective and well tolerated; more patients given cyclophosphamide had stable remissions.
Keywords: cyclosporin; cyclophosphamide; steroid-sensitive idiopathic nephrotic syndrome
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  X. Li, H. Li, J. Chen, Q. He, R. Lv, W. Lin, Q. Li, X. He, L. Qu, and W. Suya Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1919 - 1925. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Waldman, R. J. Crew, A. Valeri, J. Busch, B. Stokes, G. Markowitz, V. D'Agati, and G. Appel Adult Minimal-Change Disease: Clinical Characteristics, Treatment, and Outcomes Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 445 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. El-Husseini, F. El-Basuony, I. Mahmoud, H. Sheashaa, A. Sabry, R. Hassan, N. Taha, N. Hassan, N. Sayed-Ahmad, and M. Sobh Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience Nephrol. Dial. Transplant., November 1, 2005; 20(11): 2433 - 2438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Mahmoud, F. Basuni, A. Sabry, A. El-Husseini, N. Hassan, N. S. Ahmad, M. Elbaz, F. Moustafa, and M. Sobh Single-centre experience with cyclosporin in 106 children with idiopathic focal segmental glomerulosclerosis Nephrol. Dial. Transplant., April 1, 2005; 20(4): 735 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. W. Branten, G. Vervoort, and J. F. M. Wetzels Serum creatinine is a poor marker of GFR in nephrotic syndrome Nephrol. Dial. Transplant., April 1, 2005; 20(4): 707 - 711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Duncan, A. Dhaygude, J. Owen, T. D. H. Cairns, M. Griffith, A. G. McLean, A. Palmer, and D. Taube Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy Nephrol. Dial. Transplant., December 1, 2004; 19(12): 3062 - 3067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Cattran, T. Neogi, R. Sharma, E. T. McCarthy, and V. J. Savin Serial Estimates of Serum Permeability Activity and Clinical Correlates in Patients with Native Kidney Focal Segmental Glomerulosclerosis J. Am. Soc. Nephrol., February 1, 2003; 14(2): 448 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. Nachman and J. Martin Developments in the Immunotherapy of Glomerular Disease Journal of Pharmacy Practice, December 1, 2002; 15(6): 472 - 489. [Abstract] [PDF]
|
|
|
|
 |
|
 J.-C. Bystryn and N. M. Steinman The Adjuvant Therapy of Pemphigus: An Update Arch Dermatol, February 1, 1996; 132(2): 203 - 212. [Abstract] [PDF]
|
|